Jacobs Levy Equity Management Inc. bought a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 1st quarter, HoldingsChannel reports. The fund bought 119,304 shares of the specialty pharmaceutical company’s stock, valued at approximately $17,055,000.
Other hedge funds have also recently modified their holdings of the company. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in shares of Jazz Pharmaceuticals during the 1st quarter worth about $25,000. Prime Capital Investment Advisors LLC bought a new stake in shares of Jazz Pharmaceuticals during the 1st quarter worth about $27,000. Carroll Financial Associates Inc. boosted its stake in shares of Jazz Pharmaceuticals by 166.7% during the 1st quarter. Carroll Financial Associates Inc. now owns 200 shares of the specialty pharmaceutical company’s stock worth $28,000 after acquiring an additional 125 shares in the last quarter. Osborn Williams & Donohoe LLC bought a new stake in shares of Jazz Pharmaceuticals during the 1st quarter worth about $33,000. Finally, Moody National Bank Trust Division bought a new stake in shares of Jazz Pharmaceuticals during the 1st quarter worth about $40,000. 90.24% of the stock is currently owned by institutional investors.
Several research firms have recently issued reports on JAZZ. BidaskClub downgraded Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday. Barclays began coverage on Jazz Pharmaceuticals in a research note on Tuesday. They set an “overweight” rating and a $164.00 price target for the company. Piper Jaffray Companies set a $202.00 price target on Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, May 28th. HC Wainwright reiterated a “hold” rating and set a $153.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, May 10th. Finally, ValuEngine upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 8th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $181.06.
NASDAQ:JAZZ traded down $0.24 during mid-day trading on Friday, hitting $130.07. 3,822 shares of the company’s stock traded hands, compared to its average volume of 477,619. Jazz Pharmaceuticals PLC has a 12 month low of $113.52 and a 12 month high of $184.00. The company has a market cap of $7.38 billion, a price-to-earnings ratio of 10.65, a PEG ratio of 1.02 and a beta of 1.10. The company has a quick ratio of 3.01, a current ratio of 3.15 and a debt-to-equity ratio of 0.63.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $3.27 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.44. Jazz Pharmaceuticals had a return on equity of 27.35% and a net margin of 24.88%. The firm had revenue of $508.19 million during the quarter, compared to the consensus estimate of $466.55 million. During the same quarter in the prior year, the company earned $2.98 EPS. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. Analysts anticipate that Jazz Pharmaceuticals PLC will post 13.24 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was first reported by Riverton Roll and is the property of of Riverton Roll. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://rivertonroll.com/news/2019/06/14/jacobs-levy-equity-management-inc-buys-shares-of-119304-jazz-pharmaceuticals-plc-nasdaqjazz.html.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: How to Invest in the Dividend Aristocrat Index
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.